Value Based Access Real Endpoints positions itself as a market access partner for pharma and diagnostics, helping define a product's value for patients and payers and translate that value into coverage and innovative contracting while enabling real patient access to new diagnostics and medicines. This creates opportunities to sell end-to-end market access programs, from value articulation to pricing strategy and risk-sharing design, and to embed RE Assist into product launch workflows.

Patient Access Platform RE Assist is a tech-enabled platform that uses a proprietary AI crawler plus human curation to identify copay and deductible assistance sources for patients and caregivers. This offering can be bundled with client patient support programs to boost affordability and uptake, and can scale across multiple products for lifecycle management, appealing to manufacturers seeking scalable access solutions.

Credibility Edge Credibility from recent awards and leadership hires can shorten sales cycles with payers and biopharma customers. The addition of a Senior Advisor for payer insights and a VP of Marketing signals a stronger go-to-market and provides networks and expertise to accelerate discussions around value messaging, pricing, and access.

Mid-market Focus With a lean team and a focus on small to mid-market players, Real Endpoints can act as a strategic, cost-efficient partner for biopharma and diagnostics firms that may lack extensive market access capabilities. Engagement models such as advisory sprints or ongoing market access support offer flexible pathways to expand the customer base.

Market Alignment The offering aligns with market trends toward value-based care, outcomes-driven pricing, and payer consolidation. By delivering objective economic assessments, practical evidence strategies, and innovative contracting approaches, Real Endpoints helps clients demonstrate economic value and win favorable reimbursement, creating opportunities to reach new accounts and geographies.